No Data
HIGHTIDE-B: 2024 ANNUAL REPORT
HIGHTIDE-B (02511.HK): The two phase 3 clinical trials of ursodeoxycholic acid (HTD1801) in patients with type 2 diabetes achieved their primary endpoints.
Gelonghui, April 15 - HIGHTIDE-B (02511.HK) announced that its independently developed intestinal and hepatic anti-inflammatory and metabolic regulator, ursodeoxycholic acid berberine (HTD1801), has reached the primary efficacy endpoints and multiple secondary efficacy endpoints in two Phase 3 clinical trials (SYMPHONY 1 and SYMPHONY 2) conducted among patients with type 2 diabetes (T2DM) in China. The results of these two Phase 3 clinical trials fully demonstrate that HTD1801 has multiple therapeutic effects and provides comprehensive benefits for T2DM patients. Based on the positive clinical trial data released this time, HIGHTIDE-B...
Express News | HighTide Therapeutics Inc - Two Phase 3 Trials of Berberine Ursodeoxycholate Met Their Primary Endpoints and Gated Secondary Endpoints
HIGHTIDE-B: ANNUAL RESULTS ANNOUNCEMENTFOR THE YEAR ENDED DECEMBER 31, 2024
HIGHTIDE-B (02511.HK) will hold a Board of Directors meeting on March 28 to review and approve the annual performance.
Gelonghui reported on March 14 that HIGHTIDE-B (02511.HK) announced that the Board of Directors meeting will be held on March 28, 2025 (Friday) to review and approve the audited annual performance of the company and its subsidiaries for the year ended December 31, 2024, and its release, as well as to address Other matters.
What does AI pharmaceuticals still lack before a market explosion? | Focus
① From the discovery of targets to the identification of preclinical candidate compounds, current generative AI mainly focuses on the early stages of drug development, which can lead to significant acceleration; ② If AI in drug development is to further expand the realm of possibilities, it must explore more profitable real-world applications.
